Dehydrosertindole | CAS#173294-84-3 | Sertindole metabolite

MedKoo Cat#: 599299 | Name: Dehydrosertindole

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dehydrosertindole is a metabolite of Sertindole, an antipsychotic agent that is used to treat patients with schizophrenia. Dehydrosertindole inhibits limbic dopamine function and has high affinity for dopamine D2 receptors, serotonin 5-hydroxytryptamine (5-HT) 2 receptors and α1-adrenergic receptors.

Chemical Structure

Dehydrosertindole

CAS#173294-84-3

Theoretical Analysis

MedKoo Cat#: 599299

Name: Dehydrosertindole

CAS#: 173294-84-3

Chemical Formula: C24H24ClFN4O

Exact Mass: 438.1623

Molecular Weight: 438.93

Elemental Analysis: C, 65.67; H, 5.51; Cl, 8.08; F, 4.33; N, 12.76; O, 3.64

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Dehydrosertindole; J711.521K; LU 28-092; LU-28-092; LU28-092;

IUPAC/Chemical Name

1-(2-(4-(5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl)piperidin-1-yl)ethyl)-1,3-dihydro-2H-imidazol-2-one

InChi Key

UWVZAIBLBVMRAN-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H24ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,9,12,15-17H,7-8,10-11,13-14H2,(H,27,31)

SMILES Code

O=C1NC=CN1CCN2CCC(C3=CN(C4=CC=C(F)C=C4)C5=C3C=C(Cl)C=C5)CC2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 438.93 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Bundgaard C, Larsen F, Kreilgaard M, Brennum LT, Olsen CK. Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response. Biopharm Drug Dispos. 2009 May;30(4):209-20. doi: 10.1002/bdd.656. PubMed PMID: 19475539. 2: Canal-Raffin M, Déridet E, Titier K, Frakra E, Molimard M, Moore N. Simplified ultraviolet liquid chromatographic method for determination of sertindole, dehydrosertindole and norsertindole, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jan 5;814(1):61-7. PubMed PMID: 15607708. 3: Wong SL, Menacherry S, Mulford D, Schmitz PJ, Locke C, Granneman GR. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur J Clin Pharmacol. 1997;52(3):223-7. PubMed PMID: 9218930. 4: Canal-Raffin M, Titier K, Déridet E, Martinez B, Abouelfath A, Miras A, Gromb S, Molimard M, Moore N. Myocardium distribution of sertindole and its metabolite dehydrosertindole in guinea-pigs. Biopharm Drug Dispos. 2006 May;27(4):171-9. PubMed PMID: 16419145. 5: Olsen CK, Brennum LT, Kreilgaard M. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur J Pharmacol. 2008 Apr 28;584(2-3):318-27. doi: 10.1016/j.ejphar.2008.02.005. Epub 2008 Feb 12. PubMed PMID: 18325493. 6: Wong SL, Cao G, Mack RJ, Granneman GR. The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers. J Clin Pharmacol. 1997 Nov;37(11):1056-61. PubMed PMID: 9505999. 7: Choong E, Rudaz S, Kottelat A, Guillarme D, Veuthey JL, Eap CB. Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. J Pharm Biomed Anal. 2009 Dec 5;50(5):1000-8. doi: 10.1016/j.jpba.2009.07.007. Epub 2009 Aug 15. PubMed PMID: 19683888. 8: Subirats X, Reinstadler S, Porras SP, Raggi MA, Kenndler E. Comparison of methanol and acetonitrile as solvents for the separation of sertindole and its major metabolites by capillary zone electrophoresis. Electrophoresis. 2005 Sep;26(17):3315-24. PubMed PMID: 16097029. 9: Sakamoto K, Nakamura Y, Aikoh S, Baba T, Perregaard J, Pedersen H, Moltzen EK, Mulford DJ, Yamaguchi T. Metabolism of sertindole: identification of the metabolites in the rat and dog, and species comparison of liver microsomal metabolism. Xenobiotica. 1995 Dec;25(12):1327-43. PubMed PMID: 8719908.